An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder; Drug abuse
- Focus Therapeutic Use
- Acronyms PEACE
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 18 Aug 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 13 Jan 2010 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.